Virpax Pharmaceuticals Ownership 2024 | Who Owns Virpax Pharmaceuticals Now?


OverviewFinancialsChart

Institutional Ownership

0.00%

Insider Ownership

10.99%

Retail Ownership

89.01%

Institutional Holders

1.00

Virpax Pharmaceuticals Institutional Shareholders


Institutional Shareholders by % of Total Shares

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
PARALLEL ADVISORS, LLC0.00%-1-13-92.86%4,000Mar 31, 2024
JPMORGAN CHASE & CO----4,358-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----67-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----15,221-100.00%-Mar 31, 2024
VANGUARD GROUP INC----66,294-100.00%-Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.----100,875-100.00%-Mar 31, 2024
MORGAN STANLEY----150-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----30,500-100.00%-Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT----50,000-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----63,928-100.00%-Mar 31, 2024
BLACKROCK INC.----464-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,695-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----6,318-100.00%-Mar 31, 2024
UBS GROUP AG----6,616-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----2,400-100.00%-Mar 31, 2024
SIGNATURE RESOURCES CAPITAL MANAGEMENT, LLC----500-100.00%-Mar 31, 2024

Virpax Pharmaceuticals's largest institutional shareholder is PARALLEL ADVISORS, LLC, holding 0.00% of the company's total share outstanding, currently valued at $4.00K. The top 10 institutional shareholders own together 0.00% of the company.

Institutional Shareholders by % of Total Assets

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
PARALLEL ADVISORS, LLC0.00%-1-13-92.86%4,000Mar 31, 2024
JPMORGAN CHASE & CO----4,358-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----67-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----15,221-100.00%-Mar 31, 2024
VANGUARD GROUP INC----66,294-100.00%-Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.----100,875-100.00%-Mar 31, 2024
MORGAN STANLEY----150-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----30,500-100.00%-Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT----50,000-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----63,928-100.00%-Mar 31, 2024
BLACKROCK INC.----464-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,695-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----6,318-100.00%-Mar 31, 2024
UBS GROUP AG----6,616-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----2,400-100.00%-Mar 31, 2024
SIGNATURE RESOURCES CAPITAL MANAGEMENT, LLC----500-100.00%-Mar 31, 2024

The largest Virpax Pharmaceuticals shareholder by % of total assets is PARALLEL ADVISORS, LLC. The company owns 1.00 shares of Virpax Pharmaceuticals (VRPX), representing 0.00% of its total assets.

Institutional Buyers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
PARALLEL ADVISORS, LLC0.00%-1-13-92.86%4,000Mar 31, 2024
WELLS FARGO & COMPANY/MN----67-100.00%-Mar 31, 2024
MORGAN STANLEY----150-100.00%-Mar 31, 2024
BLACKROCK INC.----464-100.00%-Mar 31, 2024
SIGNATURE RESOURCES CAPITAL MANAGEMENT, LLC----500-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----2,400-100.00%-Mar 31, 2024
JPMORGAN CHASE & CO----4,358-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----6,318-100.00%-Mar 31, 2024
UBS GROUP AG----6,616-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,695-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----15,221-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----30,500-100.00%-Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT----50,000-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----63,928-100.00%-Mar 31, 2024
VANGUARD GROUP INC----66,294-100.00%-Mar 31, 2024
PNC FINANCIAL SERVICES GROUP, INC.----100,875-100.00%-Mar 31, 2024

As of Mar 31 2024, Virpax Pharmaceuticals's largest institutional buyer is PARALLEL ADVISORS, LLC. The company purchased -13.00 stocks of VRPX, valued at $4.00K.

Institutional Sellers

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
PNC FINANCIAL SERVICES GROUP, INC.----100,875-100.00%-Mar 31, 2024
VANGUARD GROUP INC----66,294-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----63,928-100.00%-Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT----50,000-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----30,500-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----15,221-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,695-100.00%-Mar 31, 2024
UBS GROUP AG----6,616-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----6,318-100.00%-Mar 31, 2024
JPMORGAN CHASE & CO----4,358-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----2,400-100.00%-Mar 31, 2024
SIGNATURE RESOURCES CAPITAL MANAGEMENT, LLC----500-100.00%-Mar 31, 2024
BLACKROCK INC.----464-100.00%-Mar 31, 2024
MORGAN STANLEY----150-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----67-100.00%-Mar 31, 2024
PARALLEL ADVISORS, LLC0.00%-1-13-92.86%4,000Mar 31, 2024

As of Mar 31 2024, Virpax Pharmaceuticals's biggest institutional seller is PNC FINANCIAL SERVICES GROUP, INC.. The company sold -0.10M shares of VRPX, valued at -.

Institutional New positions

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate

Institutional Sold Out

Name% Total Shares% Total AssetsCurrent SharesChange AmountChange %Market ValueDate
PNC FINANCIAL SERVICES GROUP, INC.----100,875-100.00%-Mar 31, 2024
VANGUARD GROUP INC----66,294-100.00%-Mar 31, 2024
GEODE CAPITAL MANAGEMENT, LLC----63,928-100.00%-Mar 31, 2024
SHEETS SMITH WEALTH MANAGEMENT----50,000-100.00%-Mar 31, 2024
RENAISSANCE TECHNOLOGIES LLC----30,500-100.00%-Mar 31, 2024
NORTHERN TRUST CORP----15,221-100.00%-Mar 31, 2024
TWO SIGMA SECURITIES, LLC----11,695-100.00%-Mar 31, 2024
UBS GROUP AG----6,616-100.00%-Mar 31, 2024
TOWER RESEARCH CAPITAL LLC (TRC)----6,318-100.00%-Mar 31, 2024
JPMORGAN CHASE & CO----4,358-100.00%-Mar 31, 2024
ADVISOR GROUP HOLDINGS, INC.----2,400-100.00%-Mar 31, 2024
SIGNATURE RESOURCES CAPITAL MANAGEMENT, LLC----500-100.00%-Mar 31, 2024
BLACKROCK INC.----464-100.00%-Mar 31, 2024
MORGAN STANLEY----150-100.00%-Mar 31, 2024
WELLS FARGO & COMPANY/MN----67-100.00%-Mar 31, 2024

Virpax Pharmaceuticals's largest sold out institutional shareholder by shares sold is PNC FINANCIAL SERVICES GROUP, INC., sold -0.10M shares, valued at -, as of undefined.

Virpax Pharmaceuticals Mutual Fund Holders


Name% Total AssetsTotal SharesChange AmountChange %Date
VANGUARD VALLEY FORGE FUNDS0.01%6,400--Dec 31, 2023
FIDELITY CONCORD STREET TRUST0.00%60,596--Feb 29, 2024
VANGUARD INDEX FUNDS0.00%132,58867,443103.53%Dec 31, 2023
JOHN HANCOCK VARIABLE INSURANCE TRUST0.00%556--Dec 31, 2023

Virpax Pharmaceuticals's largest mutual fund holder by % of total assets is "VANGUARD VALLEY FORGE FUNDS", owning 6.40K shares, compromising 0.01% of its total assets.

Virpax Pharmaceuticals Institutional Ownership Trends


Institutional Holdings Trend

DateHoldingsChange %
31 Mar, 241-93.75%
31 Dec, 231633.33%
30 Sep, 2312-7.69%
30 Jun, 2313-18.75%
31 Mar, 2316-11.11%
31 Dec, 221828.57%
30 Sep, 22147.69%
30 Jun, 2213-
31 Mar, 2213-18.75%
31 Dec, 211645.45%
30 Sep, 211183.33%
30 Jun, 21650.00%
31 Mar, 214-

As of 31 Mar 24, 1 institutions are holding Virpax Pharmaceuticals's shares, representing a decrease of -93.75% compared to the previous quarter.

Shares Outstanding Trend

DateShares OutstandingChange %
31 Mar, 241-100.00%
31 Dec, 23359,400-41.72%
30 Sep, 23616,674-19.42%
30 Jun, 23765,295-31.24%
31 Mar, 231,113,021-28.32%
31 Dec, 221,552,757-14.90%
30 Sep, 221,824,669-2.20%
30 Jun, 221,865,661-24.95%
31 Mar, 222,485,81511.20%
31 Dec, 212,235,462-6.24%
30 Sep, 212,384,134870.60%
30 Jun, 21245,635-10.67%
31 Mar, 21274,980-

Virpax Pharmaceuticals (VRPX) has 1.00 shares outstanding as of 31 Mar 24, down -100.00% compared to the previous quarter.

Institutional Ownership Trend

DateOwnership %Change %
31 Mar, 240.00%-
31 Dec, 233.07%11.07%
30 Sep, 235.26%12.33%
30 Jun, 236.53%7.24%
31 Mar, 239.50%5.41%
31 Dec, 2213.26%5.46%
30 Sep, 2215.58%6.14%
30 Jun, 2215.93%3.53%
31 Mar, 2221.23%1.89%
31 Dec, 2133.48%2.13%
30 Sep, 2139.66%161.64%
30 Jun, 214.95%10.20%
31 Mar, 216.97%-

As of 31 Mar 24, Virpax Pharmaceuticals is held by 0.00% institutional shareholders, representing a 0.00% growth compared to 31 Dec 23.

Institutional Increased Positions Trend

DateIncreased PositionsChange %
31 Mar, 24--100.00%
31 Dec, 2310233.33%
30 Sep, 23350.00%
30 Jun, 232-33.33%
31 Mar, 233-62.50%
31 Dec, 228100.00%
30 Sep, 224-50.00%
30 Jun, 228-
31 Mar, 228-38.46%
31 Dec, 211330.00%
30 Sep, 2110233.33%
30 Jun, 213-25.00%
31 Mar, 214-

- institutional shareholders have increased their position in VRPX stock as of 31 Mar 24 compared to 10 in the previous quarter (a -100.00% decrease).

Institutional Reduced Positions Trend

DateReduced PositionsChange %
31 Mar, 241-
31 Dec, 231-66.67%
30 Sep, 233-
30 Jun, 233-40.00%
31 Mar, 235-16.67%
31 Dec, 22650.00%
30 Sep, 224100.00%
30 Jun, 222100.00%
31 Mar, 221-50.00%
31 Dec, 212100.00%
30 Sep, 211-50.00%
30 Jun, 212-
31 Mar, 21--

1 institutional shareholders have reduced their position in VRPX stock as of 31 Mar 24 compared to 1 in the previous quarter (a 0.00% increase).

All Institutional Ownership Trend Data

DateHoldingsChange %Shares OutstandingChange %Ownership %Change %Increased PositionsChange %Reduced PositionsChange %
31 Mar, 241-93.75%1-100.00%0.00%---100.00%1-
31 Dec, 231633.33%359,400-41.72%3.07%11.07%10233.33%1-66.67%
30 Sep, 2312-7.69%616,674-19.42%5.26%12.33%350.00%3-
30 Jun, 2313-18.75%765,295-31.24%6.53%7.24%2-33.33%3-40.00%
31 Mar, 2316-11.11%1,113,021-28.32%9.50%5.41%3-62.50%5-16.67%
31 Dec, 221828.57%1,552,757-14.90%13.26%5.46%8100.00%650.00%
30 Sep, 22147.69%1,824,669-2.20%15.58%6.14%4-50.00%4100.00%
30 Jun, 2213-1,865,661-24.95%15.93%3.53%8-2100.00%
31 Mar, 2213-18.75%2,485,81511.20%21.23%1.89%8-38.46%1-50.00%
31 Dec, 211645.45%2,235,462-6.24%33.48%2.13%1330.00%2100.00%
30 Sep, 211183.33%2,384,134870.60%39.66%161.64%10233.33%1-50.00%
30 Jun, 21650.00%245,635-10.67%4.95%10.20%3-25.00%2-
31 Mar, 214-274,980-6.97%-4---

Virpax Pharmaceuticals Insider Shareholders Trades


Open Market Insider Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Open Market Insider Buys

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource

Insider Sells

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Oct 03, 2023Mathias Sheilaofficer Chief Scientific OfficerSell25,000$4.62$115.50K-
Oct 03, 2023Mathias Sheilaofficer Chief Scientific OfficerSell60,676$2.13$129.24K-
Oct 03, 2023Mathias Sheilaofficer Chief Scientific OfficerSell112,000$0.79$88.48K-

All Insider Owners Trades

DateNameRelationRoleTransactionBuy/SellSharesPriceValueShares HeldSource
Jan 31, 2024Singh Vaniladirector-A-AwardBuy25,000$0.32$7.95K25,000
Jan 31, 2024Shah Vinayofficer Chief Financial OfficerA-AwardBuy112,000$0.32$35.59K112,000
Jan 31, 2024Jambulingam Thanidirector-A-AwardBuy25,000$0.32$7.95K25,000
Jan 31, 2024Mathias Sheilaofficer Chief Scientific OfficerA-AwardBuy112,000$0.32$35.59K112,000
Jan 31, 2024Dubin Michael Fdirector-A-AwardBuy25,000$0.32$7.95K25,000
Jan 31, 2024Sendrow Jerrolddirector-A-AwardBuy25,000$0.32$7.95K25,000
Jan 31, 2024Bruce Gerald Wdirector, officer Chief Executive OfficerA-AwardBuy125,000$0.32$39.73K125,000
Jan 31, 2024Floyd Ericdirector-A-AwardBuy45,000$0.32$14.30K45,000
Jan 31, 2024Ruskin Barbaradirector-A-AwardBuy25,000$0.32$7.95K25,000
Oct 03, 2023Mathias Sheilaofficer Chief Scientific OfficerSell25,000$4.62$115.50K-
Oct 03, 2023Mathias Sheilaofficer Chief Scientific OfficerSell60,676$2.13$129.24K-
Oct 03, 2023Mathias Sheilaofficer Chief Scientific OfficerSell112,000$0.79$88.48K-
Aug 16, 2023Shah Vinayofficer Chief Financial OfficerA-AwardBuy100,000$0.99$99.00K100,000
Jun 21, 2023Shah Vinayofficer Chief Financial OfficerA-AwardBuy100,000$0.99$99.00K100,000
Jun 21, 2023Shah Vinayofficer-Buy----
Apr 26, 2023Bruce Gerald Wdirector-A-AwardBuy100,000$0.73$73.00K100,000
Mar 28, 2023Ruskin Barbaradirector-A-AwardBuy25,000$0.84$20.91K25,000
Mar 28, 2023Ruskin Barbaradirector Buy----
Feb 07, 2023Mack Anthony P.director, 10 percent owner, officer Chief Executive OfficerA-AwardBuy125,000$0.87$108.38K125,000
Jan 27, 2023Gudin Jeffreyofficer Chief Medical OfficerA-AwardBuy50,000--50,000

The last insider sell of Virpax Pharmaceuticals's stock was made by Mathias Sheila on Oct 03 2023, selling 25,000 shares at $4.62 per share (valued at $115.50K).

Virpax Pharmaceuticals Insider Ownership Trends


All Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 202491900.00%
Q2 20233--
Q1 20231011000.00%
Q2 202241400.00%
Q1 202212--
Q4 20212--
Q3 202111100.00%
Q2 202186133.33%
Q1 202121020.00%

9 total buy trades, and 1 total sell trades (buy/sell ratio of 9.00%) were made by Virpax Pharmaceuticals's insiders, as of Q1 2024.

Open Market Insider Trades Trend

DateBuySellBuy/Sell Ratio
Q1 2024---
Q2 2023---
Q1 2023---
Q2 20223--
Q1 2022---
Q4 20212--
Q3 2021---
Q2 2021---
Q1 20212--

As of Q1 2024, Insider owners conducted 0 open market buy trades and 0 open market sell trades of Virpax Pharmaceuticals's stocks.

Virpax Pharmaceuticals Peer Ownership


TickerCompany
BDRXBiodexa Pharmaceuticals Plc
VRAXVirax Biolabs Group Limited
QNRXQuoin Pharmaceuticals, Ltd.
NTRBNutriband Inc.
PALIPalisade Bio, Inc.
PBLAPanbela Therapeutics, Inc.
LGVNLongeveron Inc.
KPRXKiora Pharmaceuticals, Inc.
RNXTRenovoRx, Inc.
BWVOnconetix, Inc.
KTTAPasithea Therapeutics Corp.
REVBRevelation Biosciences, Inc.
PRAXPraxis Precision Medicines, Inc.
HILSTharimmune, Inc.
ABIOARCA biopharma, Inc.

VRPX Ownership FAQ


Virpax Pharmaceuticals is owned by institutional shareholders (0.00%), insiders (10.99%), and public (89.01%). The largest institutional shareholder of Virpax Pharmaceuticals is PARALLEL ADVISORS, LLC (0.00% of total shares) and the top mutual fund owner is VANGUARD VALLEY FORGE FUNDS (0.01% of total shares).

Virpax Pharmaceuticals's major institutional shareholders are PARALLEL ADVISORS, LLC, JPMORGAN CHASE & CO, WELLS FARGO & COMPANY/MN, NORTHERN TRUST CORP, and VANGUARD GROUP INC. The top five shareholders own together 0.00% of the company's share outstanding.

As of Mar 2024, there are 1 institutional shareholders of Virpax Pharmaceuticals.

PARALLEL ADVISORS, LLC owns 1 shares of Virpax Pharmaceuticals, representing 0.00% of the company's total shares outstanding, valued at $4K (as of Mar 2024).

As of Mar 2024, JPMORGAN CHASE & CO holds 0 shares of Virpax Pharmaceuticals (VRPX), compromising 0% of the company, valued at $0.

WELLS FARGO & COMPANY/MN is the third largest holder of Virpax Pharmaceuticals. The company owns 0 of the company's shares outstanding (worth $0).